Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
1.
Insect Mol Biol ; 23(4): 511-26, 2014 Aug.
Article in English | MEDLINE | ID: mdl-24707894

ABSTRACT

The pollen beetle Meligethes aeneus is the most important coleopteran pest in European oilseed rape cultivation, annually infesting millions of hectares and responsible for substantial yield losses if not kept under economic damage thresholds. This species is primarily controlled with insecticides but has recently developed high levels of resistance to the pyrethroid class. The aim of the present study was to provide a transcriptomic resource to investigate mechanisms of resistance. cDNA was sequenced on both Roche (Indianapolis, IN, USA) and Illumina (LGC Genomics, Berlin, Germany) platforms, resulting in a total of ∼53 m reads which assembled into 43 396 expressed sequence tags (ESTs). Manual annotation revealed good coverage of genes encoding insecticide target sites and detoxification enzymes. A total of 77 nonredundant cytochrome P450 genes were identified. Mapping of Illumina RNAseq sequences (from susceptible and pyrethroid-resistant strains) against the reference transcriptome identified a cytochrome P450 (CYP6BQ23) as highly overexpressed in pyrethroid resistance strains. Single-nucleotide polymorphism analysis confirmed the presence of a target-site resistance mutation (L1014F) in the voltage-gated sodium channel of one resistant strain. Our results provide new insights into the important genes associated with pyrethroid resistance in M. aeneus. Furthermore, a comprehensive EST resource is provided for future studies on insecticide modes of action and resistance mechanisms in pollen beetle.


Subject(s)
Coleoptera/drug effects , Coleoptera/genetics , Cytochrome P-450 Enzyme System/genetics , Enzyme Induction/drug effects , Insecticide Resistance/physiology , Insecticides/pharmacology , Pyrethrins/pharmacology , Animals , Base Sequence , Coleoptera/enzymology , Expressed Sequence Tags , Insecticide Resistance/genetics , Molecular Sequence Data , Mutation , Transcriptome , Voltage-Gated Sodium Channels/genetics
2.
J Mol Med (Berl) ; 85(5): 471-80, 2007 May.
Article in English | MEDLINE | ID: mdl-17226044

ABSTRACT

Tibolone, a tissue-selective compound with a combination of estrogenic, progestagenic, and androgenic properties, is used as an alternative for estrogen or estrogen plus progesterone hormone therapy for the treatment of symptoms associated with menopause and osteoporosis. The current study compares the endometrial gene expression profiles after short-term (21 days) treatment with tibolone to the profiles after treatment with estradiol-only (E(2)) and E(2) + medroxyprogesterone acetate (E(2) + MPA) in healthy postmenopausal women undergoing hysterectomy for endometrial prolapse. The impact of E(2) treatment on endometrial gene expression (799 genes) was much higher than the effect of tibolone (173 genes) or E(2) + MPA treatment (174 genes). Furthermore, endometrial gene expression profiles after tibolone treatment show a weak similarity to the profiles after E(2) treatment (overlap 72 genes) and even less profile similarity to E(2) + MPA treatment (overlap 17 genes). Interestingly, 95 tibolone-specific genes were identified. Translation of profile similarity into biological processes and pathways showed that ER-mediated downstream processes, such as cell cycle and cell proliferation, are not affected by E2 + MPA, slightly by tibolone, but are significantly affected by E(2). In conclusion, tibolone treatment results in a tibolone-specific gene expression profile in the human endometrium, which shares only limited resemblance to E(2) and even less resemblance to E2 + MPA induced profiles.


Subject(s)
Endometrium/drug effects , Estradiol/adverse effects , Estrogen Replacement Therapy/adverse effects , Hysterectomy, Vaginal , Medroxyprogesterone/adverse effects , Norpregnenes/adverse effects , Signal Transduction/drug effects , Uterine Prolapse/drug therapy , Cluster Analysis , Drug Therapy, Combination , Endometrium/metabolism , Endometrium/surgery , Female , Gene Expression/drug effects , Gene Expression Profiling/methods , Gene Regulatory Networks/drug effects , Humans , Oligonucleotide Array Sequence Analysis , Polymerase Chain Reaction , Postmenopause , RNA, Messenger/metabolism , Reproducibility of Results , Sex Hormone-Binding Globulin/metabolism , Signal Transduction/genetics , Uterine Prolapse/metabolism , Uterine Prolapse/surgery
3.
J Mol Endocrinol ; 37(3): 405-13, 2006 Dec.
Article in English | MEDLINE | ID: mdl-17170081

ABSTRACT

Tibolone, a steroidogenic compound with both estrogenic and progestagenic properties, is used as an alternative for estrogen or estrogen plus progesterone hormone therapy for the treatment of symptoms associated with menopause and osteoporosis. We have evaluated whether the effect of tibolone on a human endometrial cell line is similar to, or comparable with, the effect of estradiol (E(2)), medroxyprogesterone acetate (MPA) or E(2) + MPA treatment. Using stable transfection techniques, the estrogen receptor (ER) expressing human endometrial cancer cell line, ECC1, was altered to also express both progesterone receptors (PRs). These cells were then used to assess growth regulation and expression profiling (Affymetrix U133plus2) under the influence of E(2) (1 nM), MPA (1 nM), E(2) + MPA or tibolone (100 nM). Growth assessment and comparison of profiles indicate that tibolone behaves predominantly like MPA. Furthermore, regulation of prereplication complex genes, such as the minichromosome maintenance genes, could be involved in the observed strong inhibition of growth by tibolone as well as MPA. In addition, in total, 15 genes were found to be specific for tibolone treatment. These genes were predominantly involved in regulation of the cell cycle and differentiation.


Subject(s)
Endometrial Neoplasms/genetics , Endometrial Neoplasms/pathology , Estrogens/metabolism , Gene Expression Regulation, Neoplastic/drug effects , Hormone Replacement Therapy , Medroxyprogesterone Acetate/pharmacology , Norpregnenes/pharmacology , Progesterone/metabolism , Cell Line, Tumor , Cell Proliferation/drug effects , Endometrial Neoplasms/metabolism , Estrogens/pharmacology , Female , Gene Expression Profiling , Humans , Oligonucleotide Array Sequence Analysis , Progesterone/pharmacology , Transcription, Genetic/drug effects , Transcription, Genetic/genetics
4.
J Med Chem ; 40(22): 3594-600, 1997 Oct 24.
Article in English | MEDLINE | ID: mdl-9357526

ABSTRACT

The diketopiperazine "C5" conformational mimic has been incorporated into the L-prolyl-L-leucylglycinamide (PLG, 1) structure and into the bicyclic lactam PLG peptidomimetic structure 3 to give compounds 5 and 6, respectively. These analogues were designed to explore the idea that the N-terminal "C5" conformation, which was found in the crystal structure of 2 and which was mimicked in 4 by the diketopiperazine function, was a factor in the high potency of these two agents. Through the use of the [3H]spiroperidol/N-propylnorapomorphine (NPA) D2 receptor competitive binding assay, both 5 and 6 were found to increase the affinity of the dopamine receptor for agonists and both were found to increase the percentage of D2 receptors which existed in the high-affinity state. These effects were observed when Gpp(NH)p was either absent or present, and they were analogous to the effects observed previously for PLG and the PLG peptidomimetics 2 and 4. However, the potency seen with 5 and 6 was less than that seen for 2 and 4, suggesting that while the N-terminal "C5" conformation may play a role in the potency of the gamma-lactam peptidomimetics of PLG, it does not appear to be the primary factor. In the 6-hydroxydopamine-lesioned animal model of Parkinson's disease, 5 altered apomorphine-induced rotational behavior in a dose-dependent manner. The maximum effect occurred at a dose of 0.01 mg/kg i.p. and resulted in a 52.27 +/- 13.96% (p < 0.001, n = 7) increase in rotations compared to apomorphine administered alone.


Subject(s)
Dopamine Agents/pharmacology , MSH Release-Inhibiting Hormone/analogs & derivatives , Piperazines/chemistry , Receptors, Dopamine/drug effects , Animals , Behavior, Animal/drug effects , Cattle , Corpus Striatum/drug effects , Diketopiperazines , Dopamine Agents/chemical synthesis , Dopamine Agents/chemistry , Drug Design , In Vitro Techniques , MSH Release-Inhibiting Hormone/chemical synthesis , MSH Release-Inhibiting Hormone/pharmacology , Magnetic Resonance Spectroscopy , Male , Molecular Mimicry , Molecular Structure , Rats , Rats, Sprague-Dawley , Spectrometry, Mass, Fast Atom Bombardment , X-Ray Diffraction
5.
Mayo Clin Proc ; 75(11): 1209-13, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11075754

ABSTRACT

Catastrophic neurologic events occur rarely postoperatively and must be diagnosed quickly. A 63-year-old woman who had undergone uneventful total hip arthroplasty experienced obtundation after admission to the postanesthesia care unit. Cranial magnetic resonance imaging revealed multiple lesions consistent with ischemia or infarction, and fat cerebral embolism was diagnosed. We describe the numerous complications that may occur in patients in the postanesthesia care unit and review the differential diagnosis of altered mental status in such patients. Paradoxical cerebral fat embolization must be considered in the differential diagnosis of altered mental status after pelvic or long bone fracture or lower extremity major joint replacement, and this condition may occur despite normal pulmonary function and no patent foramen ovale or right-to-left intracardiac shunt. Magnetic resonance imaging with T2-weighted sequences is the cranial imaging study of choice for early evaluation of patients with sudden multifocal neurologic deficits and suspected fat embolism syndrome.


Subject(s)
Arthroplasty, Replacement, Hip , Consciousness Disorders/etiology , Embolism, Fat/etiology , Intracranial Embolism/etiology , Postoperative Complications , Anesthesia Recovery Period , Consciousness Disorders/diagnosis , Diagnosis, Differential , Female , Humans , Magnetic Resonance Imaging , Middle Aged
6.
Microsc Res Tech ; 51(3): 214-27, 2000 Nov 01.
Article in English | MEDLINE | ID: mdl-11054872

ABSTRACT

The laminins form a large family of modular proteins found in basement membranes, but also elsewhere. They function as structural components and are essential for morphogenesis, but in addition interact with cell surface receptors such as integrins and alpha-dystroglycan. By virtue of their receptor interactions, they initiate intracellular signalling events that regulate cellular organization and differentiation. The many interactions of laminins are mediated by binding sites, often contributed by single domains, which may differ between different forms of laminin. In the present article, we describe how the diversity of laminins and the genetic regulation of the expression of different laminin forms lead to the formation of extracellular matrices with variable laminin composition and thereby different biological properties.


Subject(s)
Laminin/chemistry , Laminin/genetics , Alternative Splicing , Amino Acid Sequence , Animals , Basement Membrane/metabolism , Cytoskeletal Proteins/metabolism , Dystroglycans , Gene Expression Regulation , Humans , Integrins/metabolism , Laminin/metabolism , Membrane Glycoproteins/chemistry , Membrane Glycoproteins/metabolism , Molecular Sequence Data , Protein Isoforms/chemistry , Protein Isoforms/genetics , Protein Isoforms/metabolism
7.
Peptides ; 21(2): 301-8, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10764960

ABSTRACT

Acute treatment of rats with haloperidol results in a rapid and transient increase in striatal c-fos mRNA and Fos immunoreactivity. The induction of immediate early genes by haloperidol may be involved in the development of extrapyramidal side effects. L-Prolyl-L-leucyl-glycinamide (PLG, or MIF-1) has been observed to antagonize the development of haloperidol-induced D(2) receptor supersensitivity in rats. We investigated the modulatory effects of PLG on haloperidol-induced c-fos and Fos protein expression in the rat striatum. We report that coadministration of either PLG or the potent analog of PLG, 3(R)-[(2(S)-pyrrolidylcarbonyl)amino]-2-oxo-1-pyrrolidineacetam ide (PAOPA), attenuated haloperidol-induced c-fos and Fos expression. Haloperidol induced [2 mg/kg, intraperitoneally (i.p.)] c-fos and Fos expression by 500% and 100%, respectively. These responses were attenuated by 170% and 75%, respectively, when coadministered with PLG (20 mg/kg, i.p.) or by 79% by PAOPA (10 microg/kg, i.p.).


Subject(s)
Corpus Striatum/drug effects , Hormone Antagonists/pharmacology , MSH Release-Inhibiting Hormone/pharmacology , Proto-Oncogene Proteins c-fos/genetics , Pyrrolidinones/pharmacology , Animals , Gene Expression Regulation/drug effects , Haloperidol/antagonists & inhibitors , Haloperidol/pharmacology , MSH Release-Inhibiting Hormone/analogs & derivatives , Male , Molecular Structure , Peptides/pharmacology , Proto-Oncogene Proteins c-fos/metabolism , RNA, Messenger/drug effects , Rats , Rats, Sprague-Dawley
8.
Ann Thorac Surg ; 72(5): 1758-60, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11722090

ABSTRACT

Twenty-five percent of primary hyperparathyroidism is caused by ectopic mediastinal parathyroid glands, with 2% of these not accessible to standard cervical surgical approaches. Advancement in video-assisted thoracoscopic surgical techniques has decreased the need for sternotomy to successfully remove these ectopic glands. The thoracoscopic approach, however, is limited by the surgeon's inability to always accurately visualize ectopic glands. Intraoperative radionuclide-guided dissection, using a thoracoscopic approach, provides a novel adjunct to the removal of occult ectopic parathyroid glands. We report a case of an occult ectopic parathyroid adenoma removed thoracoscopically using an intraoperative handheld gamma probe.


Subject(s)
Adenoma/diagnostic imaging , Adenoma/surgery , Choristoma/diagnostic imaging , Choristoma/surgery , Intraoperative Care , Mediastinal Diseases/diagnostic imaging , Mediastinal Diseases/surgery , Parathyroid Glands , Parathyroid Neoplasms/diagnostic imaging , Parathyroid Neoplasms/surgery , Thoracoscopy/methods , Female , Humans , Middle Aged , Radionuclide Imaging
9.
Brain Res ; 737(1-2): 287-91, 1996 Oct 21.
Article in English | MEDLINE | ID: mdl-8930377

ABSTRACT

Melanocyte stimulating hormone release inhibiting factor (MIF-1), also known as L-prolyl-L-leucyl-glycinamide (PLG), has previously been found to have the ability to modulate dopamine D2-receptor agonist binding both in the striatum and limbic regions. In the present study the 6-hydroxydopamine unilateral lesion model of apomorphine-induced rotational behaviour, in Wistar rats, was used to assess the dopaminergic modulatory activity of PLG and two novel analogues, L-prolyl-L-prolyl-L-prolinamide (analogue A) and (2S, 5R, 7R)-1-Aza-7[3'(S)-1-(2',5'-dioxo-pyrrolidino[2,1-c]piperazino++ +)] -8-oxo-4-thiabicyclo[3.30]octane-2-carboxamide (analogue B). PLG and the two novel analogues showed a bell-shaped dose-response relationship, suggesting that analogue A, B and PLG all manifest their effect through a similar mechanism and exhibit a window of therapeutic efficacy. Analogue A was a 100 times, while analogue B was 10 times, more potent than PLG in increasing the contralateral rotational response when given in combination with apomorphine. Analogue A was also more efficacious than PLG or analogue B at increasing apomorphine-induced contralateral rotations. Intrastriatal administration of either analogue A or B resulted in a greater increase in apomorphine-induced rotations than the most efficacious intraperitoneally delivered dose. The results of the present study suggest that PLG and its two novel analogues are able to modulate dopamine receptor activity and may be possible therapeutic agents for the treatment of Parkinsonian symptoms as well as tardive dyskinesia.


Subject(s)
Dopamine/physiology , MSH Release-Inhibiting Hormone/pharmacology , Synaptic Transmission/drug effects , Animals , Apomorphine/pharmacology , Behavior, Animal/drug effects , Dopamine Agonists/pharmacology , Dose-Response Relationship, Drug , MSH Release-Inhibiting Hormone/analogs & derivatives , Male , Neuropeptides , Oxidopamine , Rats , Rats, Wistar , Rotation , Sympatholytics
10.
Postgrad Med ; 110(5): 81-4, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11727654

ABSTRACT

Tympanic membrane perforation is a common and potentially serious condition. One of the most important aspects of primary care for perforations is deciding which patients need to be seen by an otolaryngologist and how urgently they need to be referred. There are several indications for surgical repair, but most cases can be managed with conservative care and require no referral.


Subject(s)
Primary Health Care , Tympanic Membrane Perforation/therapy , Adult , Deafness/etiology , Deafness/prevention & control , Humans , Tympanic Membrane Perforation/complications , Tympanic Membrane Perforation/etiology
11.
Headache ; 41(3): 235-47, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11264683

ABSTRACT

The increasing popularity of scuba diving has added a new category to the differential diagnosis of headache. Headache in divers, while uncommon and generally benign, can occasionally signify serious consequences of hyperbaric exposure such as arterial gas embolism, decompression sickness, and otic or paranasal sinus barotrauma. Inadequate ventilation of compressed gases can lead to carbon dioxide accumulation, cerebral vasodilatation, and headache. Other types of headache encountered in divers include exertional headache, cold stimulus headache, migraine, tension-type headache, acute traumatic headache, cervicogenic headache, carbon monoxide poisoning headache, and headache associated with envenomation. Correct diagnosis and appropriate treatment require a careful history and neurologic examination as well as an understanding of the unique physiologic stresses of the subaquatic environment.


Subject(s)
Decompression Sickness/complications , Diving/adverse effects , Diving/injuries , Headache/etiology , Animals , Animals, Poisonous , Barotrauma/complications , Carbon Monoxide Poisoning/complications , Decompression Sickness/diagnosis , Diagnosis, Differential , Headache/diagnosis , Headache/drug therapy , Humans , Hypercapnia/complications , Hypnotics and Sedatives/adverse effects , Hypnotics and Sedatives/therapeutic use , Migraine Disorders/complications , Migraine Disorders/diagnosis
SELECTION OF CITATIONS
SEARCH DETAIL